Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price Crosses Below 200-Day Moving Average – What’s Next?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)’s share price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $4.26 and traded as low as $3.46. Bolt Biotherapeutics shares last traded at $3.46, with a volume of 19,918 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Friday, July 17th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $14.50.

Bolt Biotherapeutics Trading Up 0.6%

The stock has a fifty day moving average of $3.76 and a 200 day moving average of $4.26. The company has a market capitalization of $6.99 million, a P/E ratio of -0.22 and a beta of 1.09. The company has a debt-to-equity ratio of 1.47, a quick ratio of 2.61 and a current ratio of 2.61.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($4.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.39) by ($1.18). Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.50 million. As a group, equities research analysts anticipate that Bolt Biotherapeutics, Inc. will post -11.1 EPS for the current fiscal year.

Insiders Place Their Bets

In other Bolt Biotherapeutics news, CEO William Quinn sold 9,132 shares of Bolt Biotherapeutics stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $3.24, for a total transaction of $29,587.68. Following the transaction, the chief executive officer owned 25,384 shares of the company’s stock, valued at $82,244.16. The trade was a 26.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 38,584 shares of company stock worth $128,361 over the last quarter. 9.40% of the stock is owned by insiders.

Institutional Trading of Bolt Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of BOLT. Nan Fung Group Holdings Ltd purchased a new position in shares of Bolt Biotherapeutics during the 2nd quarter valued at $19,250. T3 Companies LLC purchased a new position in shares of Bolt Biotherapeutics in the fourth quarter valued at about $208,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Bolt Biotherapeutics by 40.3% in the first quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock worth $312,000 after acquiring an additional 22,200 shares during the period. 86.70% of the stock is currently owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s platform is designed to stimulate the body’s innate and adaptive immune systems to recognize and attack tumor cells.

Bolt’s technology includes Boltbody™ immune-stimulating antibody conjugates, or ISACs. These therapies are intended to combine the targeting capabilities of antibodies with immune-activating components that can recruit and enhance the activity of immune cells within the tumor microenvironment.

The company’s development programs have included BDC-1001, an investigational HER2-targeted ISAC for the treatment of HER2-expressing solid tumors, and BDC-3042, an investigational antibody intended to activate macrophages through the Dectin-2 pathway.